Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

172
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
172
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

321
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
321

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding insulin-like peptide 5 (INSL5) and relaxin family peptide receptor 4 (RXFP4): structure, signalling, and function.

RSC chemical biology·2026
Same author

Development and Biological Characterization of Fluorescent Dynorphins for the Visualization of Kappa Opioid Receptors.

Journal of medicinal chemistry·2026
Same author

Fluorinated Hypercrosslinked Polymers with Exceptional Capacity for Perfluorooctanoic Acid Removal from Water.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

GRIPHIN: grids of pharmacophore interaction fields for affinity prediction.

Journal of cheminformatics·2026
Same author

Frequent expression of aberrant chimeric Cdkn2a transcripts in mouse models of muscular dystrophy.

Scientific reports·2026
Same author

The phytochemical analysis of <i>Carissa macrocarpa</i>, cytotoxic potential of fractions, and the molecular modulation on p53 expression in HT-29 and LS174T cell lines.

Artificial cells, nanomedicine, and biotechnology·2026
Same journal

Correction: Reis et al. Bioinks Enriched with ECM Components Obtained by Supercritical Extraction. <i>Biomolecules</i> 2022, <i>12</i>, 394.

Biomolecules·2026
Same journal

Correction: Kim, K.-H.; Yoo, B.C. Gintonin as a Lysophosphatidic Acid-Enriched GPCR Ligand System: Molecular Architecture and Receptor Pharmacology in <i>Panax ginseng</i>. <i>Biomolecules</i> 2026, <i>16</i>, 465.

Biomolecules·2026
Same journal

Correction: Bastyte et al. The Association of Vitamin D Receptor Gene Polymorphisms with Vitamin D, Total IgE, and Blood Eosinophils in Patients with Atopy. <i>Biomolecules</i> 2024, <i>14</i>, 212.

Biomolecules·2026
Same journal

AtHSPR Plays a Positive Role in Arabidopsis Resistance Against <i>Pseudomonas syringae</i> pv. <i>tomato</i> DC3000 by Interacting with TOP1.

Biomolecules·2026
Same journal

CYTH4 Facilitates Renal Cell Carcinoma via Enhancing Proliferation and Likely Immune Evasion.

Biomolecules·2026
Same journal

Integrated Immune-Gut Profiling Identifies an Exploratory Pediatric Inflammatory Intestinal Profile Associated with Food-Specific IgG Reactivity.

Biomolecules·2026
See all related articles

Related Experiment Video

Updated: Aug 5, 2025

Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease
10:19

Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease

Published on: August 22, 2014

14.3K

Low-Affinity/High-Selectivity Dopamine Transport Inhibition Sufficient to Rescue Cognitive Functions in the Aging

Jana Lubec1, Ahmed M Hussein1,2,3, Predrag Kalaba2

  • 1Programme for Proteomics, Paracelsus Medical University, 5020 Salzburg, Austria.

Biomolecules
|March 29, 2023
PubMed
Summary
This summary is machine-generated.

A novel, highly selective dopamine transporter inhibitor, S-CE-123, shows potential for treating age-related cognitive decline. This compound improved cognitive function in aged rats without adverse effects, suggesting a promising therapeutic avenue.

Keywords:
DATagingdopaminelearning and memoryreward

More Related Videos

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

25.9K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.4K

Related Experiment Videos

Last Updated: Aug 5, 2025

Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease
10:19

Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease

Published on: August 22, 2014

14.3K
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

25.9K
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.4K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Cognitive decline is a growing global concern in aging populations and psychiatric disorders.
  • Current dopamine transporter (DAT) inhibitors lack specificity, leading to undesirable side effects.
  • There is a need for targeted pharmacological treatments for cognitive dysfunction.

Purpose of the Study:

  • To synthesize and characterize a novel, enantiomerically pure, and highly selective DAT inhibitor, S-CE-123.
  • To evaluate the efficacy of S-CE-123 in enhancing or rescuing cognitive functions in aged rats.
  • To assess the safety profile and behavioral effects of S-CE-123 in rats.

Main Methods:

  • Synthesis of enantiomerically pure S-CE-123.
  • In vitro binding studies (DAT, NET, SERT), GPCR and kinome screening.
  • Pharmacokinetic and neurotoxicological assessments.
  • Cognitive function testing using a hole-board test in young and aged rats.
  • Open field studies in young rats.

Main Results:

  • S-CE-123 demonstrated low-affinity but high selectivity for dopamine reuptake inhibition with good bioavailability.
  • S-CE-123 did not induce hyperlocomotion, anxiogenic, or stereotypic behaviors in young rats.
  • Aged rats treated with S-CE-123 showed improved performance in a spatial learning task, while young rats did not.

Conclusions:

  • S-CE-123 is a selective dopamine reuptake inhibitor with a favorable safety profile.
  • The age-specific cognitive improvement suggests a potential therapeutic role in age-related cognitive decline.
  • S-CE-123 warrants further investigation as a candidate for treating cognitive dysfunction in aging and psychiatric disorders.